The functional characterization of the novel IRF-5 mutant in transformed B and T cell lines and in ATL and CLL patients may lead to a better understanding of the role of these transcriptional regulators in hematopoietic malignancies. This evidence concerns the gene IRF5 and B-cell chronic lymphocytic leukemia.